USP Botanical Identity Testing Under DSHEA: Why European Labs Almost Always Fall Short

FDA issues Warning Letters to dietary supplement companies every year, and a striking proportion of them cite the same deficiency: failure to conduct adequate identity testing on botanical ingredients. Not mislabelling, not contamination with filth — identity. The underlying regulation is unambiguous: 21 CFR Part 111.75(a)(1)(i) requires that manufacturers perform “at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient.” What “appropriate” means in practice is where European brands consistently underestimate the gap.

If you manufacture herbal products in Europe and are preparing for US market entry, your contract lab — however capable it is for EU regulatory purposes — almost certainly cannot produce the identity test documentation that FDA expects. The methods are different. The reference standards are different. And ISO 17025 accreditation, while necessary, isn’t proof that a lab has validated the specific USP chapters that DSHEA compliance demands. We see this repeatedly with European brands entering the US market: they arrive with professionally compiled technical dossiers and well-formatted COAs from established European laboratories, and their US regulatory counsel tells them to start the testing over from scratch.

This post explains why that happens — and what a compliant botanical identity package actually needs to contain.

What 21 CFR Part 111 Actually Requires for Botanical Identity

The regulatory backbone here is Title 21 of the Code of Federal Regulations, Part 111 — Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements. Section 111.75 sets the component testing requirements. For botanical dietary ingredients, compliance is not satisfied by a single organoleptic check or a basic TLC plate.

FDA’s expectation — built up through Warning Letters, FDA 483 observations, and agency guidance over more than two decades — is that botanical identity testing follows a hierarchical, multi-method approach. The primary reference is USP General Chapter <561>, “Articles of Botanical Origin,” which establishes general procedures including macroscopic examination, microscopic examination, and chemical tests. But <561> alone is no longer adequate for most commercially significant botanical ingredients.

USP General Chapter <2030>, “Botanical Dietary Supplements,” provides the comprehensive framework the industry now works to. It describes a four-tier testing sequence: organoleptic evaluation (colour, odour, taste), macroscopic identification (morphology, particle size), microscopic examination (cellular anatomy, starch granules, calcium oxalate crystals), and chemical characterisation — typically by HPLC fingerprinting or TLC densitometry against authenticated reference standards. DNA-based methods (DNA barcoding, next-generation sequencing) function as a recognised fifth tier for botanical species with documented adulteration histories.

For high-volume, high-risk botanicals — ashwagandha (Withania somnifera), elderberry (Sambucus nigra), turmeric (Curcuma longa), bilberry (Vaccinium myrtillus) — FDA inspectors increasingly expect to see chemical fingerprinting alongside morphological examination. The complete list of USP chapters relevant to a DSHEA-ready botanical testing programme includes <561>, <2030>, <232> and <233> for elemental impurities, and the microbiological enumeration chapters <60>, <61>, and <62>. Each must be performed using validated methods at an ISO 17025-accredited facility that has specifically validated those chapters. That combination is rare outside North America.

The Methods Gap Between European and US Laboratories

European laboratories are typically excellent at what they do. Many hold ISO 17025 accreditation, operate under robust quality management systems, and routinely handle complex botanical matrices. The problem isn’t competence — it’s method libraries and reference standard alignment.

European herbal testing is anchored in the European Pharmacopoeia (Ph. Eur.) and the EU herbal monographs published by the European Medicines Agency’s Committee on Herbal Medicinal Products (HMPC). These are rigorous, scientifically credible documents. But they weren’t written with DSHEA compliance in mind, and their specifications don’t always align with USP requirements — sometimes in ways that matter significantly for regulatory acceptance.

Take valerian root (Valeriana officinalis) as a concrete example. Ph. Eur. monograph 0453 specifies a TLC identity test using particular reference substances and an assay for valerenic acid content of not less than 0.17% (calculated with reference to the dried drug). USP’s monograph for Valerian uses a different reference standard solution, a different TLC system, and different content specifications. A European lab’s COA citing Ph. Eur. 0453 compliance tells an FDA investigator nothing about USP monograph compliance — because the methods have not been cross-validated as equivalent, and neither pharmacopoeia presents them as such.

The same divergence applies to echinacea, ginkgo, ginseng, and dozens of other high-volume botanicals. And for ingredients like ashwagandha — surging in popularity across European supplement brands but without an established Ph. Eur. monograph — European commercial labs sometimes fall back on in-house or supplier-developed methods with no defined relationship to USP <2030> specifications. Those methods may be scientifically sound. They are not what FDA is looking for when it opens a dossier.

DNA barcoding adds a further layer of complication. While the technique is well-accepted in North American regulatory and quality circles, relatively few European commercial laboratories maintain the validated reference DNA sequence databases and bioinformatics workflows needed to produce a DSHEA-defensible botanical identity report. The American Botanical Council’s Botanical Adulterants Prevention Program has developed guidance specifically framed around US compliance expectations for DNA-based botanical identification — guidance that most European laboratories simply aren’t working to.

The practical result: a botanical identity test conducted at a European lab may be perfectly valid for EU market compliance and genuinely rigorous by Ph. Eur. standards, while simultaneously being completely unusable for a US regulatory submission or FDA inspection response.

Contaminant Testing: Where the Limits Diverge Further

Botanical identity is the most structurally significant gap, but contaminant limits compound the problem considerably. European brands frequently assume that a clean EU contaminant COA transfers directly to US regulatory acceptability. In many cases, it doesn’t — and the differences can be quantitatively meaningful.

Mycotoxin limits are one clear area of divergence. The EU regulates aflatoxins in botanical and food ingredients under Commission Regulation (EC) No 1881/2006, setting maximum levels for aflatoxin B1 at 5 μg/kg in most dried herbs, and total aflatoxins at 10 μg/kg. FDA has no single codified numerical maximum for aflatoxins in dietary supplement botanical ingredients, but USP <561> and applicable dietary supplement monographs specify limits that can differ — for certain matrices and ingredient categories, more stringently — from EU regulatory maximums. A European lab’s mycotoxin COA, tested against EU maximum residue levels, may not flag a sample that would require remediation under a USP-specific programme.

Elemental impurities present a similar issue. USP chapters <232> and <233> use inductively coupled plasma mass spectrometry (ICP-MS) and set permitted daily exposure limits for a broad panel of elements including arsenic, cadmium, lead, and mercury. European labs may test to Ph. Eur. 2.4.20 or to EU maximum levels for food supplements — analytical approaches that differ methodologically and, for some elements, numerically. A COA showing compliance with EU lead and cadmium limits is not an equivalent document to a USP <232>/<233> impurity profile.

We’ve seen this play out with European brands that had entirely clean EU quality documentation. When testing was conducted in a North American ISO 17025-accredited laboratory against USP specifications, specific raw materials required additional scrutiny and, in some cases, prompted sourcing reviews. This isn’t about European suppliers being dishonest. It’s about two parallel regulatory frameworks that were never designed to be mutually compatible — and that have diverged further as each side has updated its limits independently.

What a DSHEA-Ready Botanical Testing Package Actually Looks Like

For a European herbal brand preparing US market entry, a DSHEA-compliant botanical testing programme needs to be built to USP specifications from the start, in a laboratory that has validated the relevant chapters. Here’s what that means in practice.

Identity testing must address all four USP <2030> tiers for each botanical ingredient: organoleptic, macroscopic, microscopic, and chemical characterisation against USP reference standards or appropriately qualified in-house standards derived from authenticated botanical material. For any ingredient with a documented adulteration history — and that list includes turmeric, elderberry, bilberry, ginseng, ashwagandha, saw palmetto, and others — DNA-based confirmation should be included. The laboratory must hold specifically validated methods for each tier, not just a general botanical testing capability.

Contaminant testing must reference USP chapter numbers and USP specification limits on the final COA. Mycotoxin testing should be performed against the limits cited in the applicable USP monograph or ingredient specification, not defaulting to EU regulatory maximums. Elemental impurity testing must follow USP <232>/<233> methodology.

Testing must occur at the component level. 21 CFR Part 111.75 requires identity verification of dietary ingredient components before they enter manufacturing — a finished-product COA does not satisfy this requirement. Every batch of each botanical ingredient needs its own compliant identity test record.

The COA format matters too. FDA investigators look for explicit USP chapter references, USP specification limits, and the analyst’s qualification. A well-formatted European-style COA citing Ph. Eur. monograph numbers is professionally produced documentation for the wrong regulatory system.

European brands that attempt to adapt their existing European lab relationships to meet these requirements usually run into the same wall: their labs are willing but haven’t validated USP methods for the specific botanical species in their formulas. Building those validations takes months and significant cost. Engaging a North American ISO 17025-accredited partner lab that already maintains a validated USP botanical testing library is consistently faster, more cost-effective, and gives FDA something it can immediately evaluate.

At Care Europe, we manage exactly this handoff. Our partner-lab network in North America works to validated USP <2030> and <561> methods and produces documentation structured for FDA compliance contexts. For European manufacturers who have spent years building EU-compliant quality systems, this isn’t about discarding what you’ve built. It’s about routing the specific testing that US regulators require through laboratories equipped to provide it — and arriving at the US border with documentation that holds up under scrutiny.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Care Europe | VP Operations, Qalitex. Learn more about our team

Talk to our team about EU market entry — and US testing readiness. Contact us

Related from our network

• Botanical Identity & Adulteration Testing at Qalitex Laboratories — ISO 17025-accredited US lab offering USP <2030>-compliant botanical identity testing, DNA barcoding, and DSHEA-ready COA documentation for supplement brands
• NHP Ingredient Testing for Canadian Market Entry at Androxa — Health Canada-compliant testing for botanical raw materials and herbal ingredients targeting the Canadian natural health product market